Cancer Res. 2001 Aug 15;61(16):6029-33.

Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.

Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, Dalmasso EA, Wright GL Jr.

Source

Department of Microbiology, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA.

Abstract

The lack of a sensitive immunoassay for quantitating serum prostate-specific membrane antigen (PSMA) hinders its clinical utility as a diagnostic/prognostic biomarker. An innovative protein biochip immunoassay was used to quantitate and compare serum PSMA levels in healthy men and patients with either benign or malignant prostate disease. PSMA was captured from serum by anti-PSMA antibody bound to ProteinChip arrays, the captured PSMA detected by surface-enhanced laser desorption/ionization mass spectrometry, and quantitated by comparing the mass signal integrals to a standard curve established using purified recombinant PSMA. The average serum PSMA value for prostate cancer (623.1 ng/ml) was significantly different (P < 0.001) from that for benign prostate hyperplasia (117.1 ng/ml) and the normal groups (age <50, 272.9 ng/ml; age >50, 359.4 ng/ml). These initial results suggest that serum PSMA may be a more effective biomarker than prostate-specific antigen for differentiating benign from malignant prostate disease and warrants additional evaluation of the surface-enhanced laser desorption/ionization PSMA immunoassay to determine its diagnostic utility.

PMID:: 11507047; [PubMed - indexed for MEDLINE]

Free full text

LinkOut - more resources

Supplemental Content

Related citations

Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer. [Clin Cancer Res. 1999]
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
Beckett ML, Cazares LH, Vlahou A, Schellhammer PF, Wright GL Jr. Clin Cancer Res. 1999 Dec; 5(12):4034-40.
Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay. [Protein Expr Purif. 2000]
Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay.
Xiao Z, Jiang X, Beckett ML, Wright GL Jr. Protein Expr Purif. 2000 Jun; 19(1):12-21.
Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. [Urology. 1998]
Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer.
Murphy GP, Kenny GM, Ragde H, Wolfert RL, Boynton AL, Holmes EH, Misrock SL, Bartsch G, Klocker H, Pointner J, et al. Urology. 1998 May; 51(5A Suppl):89-97.
Review Prostate-specific membrane antigen: current and future utility. [Semin Urol Oncol. 1998]
Review Prostate-specific membrane antigen: current and future utility.
Gregorakis AK, Holmes EH, Murphy GP. Semin Urol Oncol. 1998 Feb; 16(1):2-12.
Review Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. [Cancer. 1998]
Review Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.
Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH. Cancer. 1998 Dec 1; 83(11):2259-69.

See reviews... See all...

Cited by 10 PubMed Central articles

Novel diagnostic biomarkers for prostate cancer. [J Cancer. 2010]
Novel diagnostic biomarkers for prostate cancer.
Madu CO, Lu Y. J Cancer. 2010 Oct 6; 1:150-77. Epub 2010 Oct 6.
Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis. [Mol Med. 2011]
Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis.
Fujita N, Nakanishi M, Mukai J, Naito Y, Ichida T, Kaito M, Yoshikawa T, Takei Y. Mol Med. 2011 Jan-Feb; 17(1-2):70-8. Epub 2010 Oct 5.
Sputum proteomics in inflammatory and suppurative respiratory diseases. [Am J Respir Crit Care Med. 2008]
Sputum proteomics in inflammatory and suppurative respiratory diseases.
Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, Innes JA, Porteous DJ, Greening AP. Am J Respir Crit Care Med. 2008 Sep 1; 178(5):444-52. Epub 2008 Jun 19.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Quantitation of serum prostate-specific membrane antigen by a novel protein bioc...
Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.
Cancer Res. 2001 Aug 15 ;61(16):6029-33.

PubMed
Effects of limb-length discrepancy on gait economy and lower-extremity muscle ac...
Effects of limb-length discrepancy on gait economy and lower-extremity muscle activity in older adults.
J Bone Joint Surg Am. 2001 Jun ;83-A(6):907-15.

PubMed
Matrix metalloproteinase 28, a novel matrix metalloproteinase, is constitutively...
Matrix metalloproteinase 28, a novel matrix metalloproteinase, is constitutively expressed in human intervertebral disc tissue and is present in matrix of more degenerated discs.
Arthritis Res Ther. 2009 ;11(6):R184. Epub 2009 Dec 9 .

PubMed
Treatment with rituximab affects both the cellular and the humoral arm of the im...
Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.
Clin Immunol. 2007 Jan ;122(1):62-74. Epub 2006 Oct 13 .

PubMed
Mediators of inflammation and acute phase response in the liver.
Mediators of inflammation and acute phase response in the liver.
Cell Mol Biol (Noisy-le-grand). 2001 Jun ;47(4):661-73.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.

Source

Abstract

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Libraries

Supplemental Content

Related citations

Cited by 10 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information